Why Do Experts Solve Complex Problems Using Open Innovation? Evidence from the U.S. Pharmaceutical Industry

This article investigates how project expertise and complexity jointly impact the decision to adopt open or closed innovation. It identifies four different types of open innovation models—crowdsourcing, coopetition, science-based, and network—and explores the varying conditions of project expertise...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	California management review 2019-11, Vol.62 (1), p.144-166
Hauptverfasser:	Lee, Yeolan, Fong, Eric, Barney, Jay Bryan, Hawk, Ashton
Format:	Artikel
Sprache:	eng
Schlagworte:	Complexity Crowdsourcing Data analysis Development programs Drug development Experts Innovations Pharmaceutical industry
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	166
container_issue	1
container_start_page	144
container_title	California management review
container_volume	62
creator	Lee, Yeolan Fong, Eric Barney, Jay Bryan Hawk, Ashton
description	This article investigates how project expertise and complexity jointly impact the decision to adopt open or closed innovation. It identifies four different types of open innovation models—crowdsourcing, coopetition, science-based, and network—and explores the varying conditions of project expertise and complexity under which firms tend to adopt a particular type. Using large data analysis from pharmaceutical drug development projects, the authors find that complexity moderates the relationship between project expertise and the choice of open or closed innovation and that levels of complexity and project expertise vary between different open innovation models.
doi_str_mv	10.1177/0008125619883617
format	Article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2316377475</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0008125619883617</sage_id><sourcerecordid>2316377475</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-ccee72825c6a6dcf6672ee5e075865bb503c8942438ada6f0dcc15c56f3669f23</originalsourceid><addsrcrecordid>eNp1kM1Lw0AUxBdRsFbvHhc8p-5ush85idSqhUILtXgM281Lm5pk425S2v_ehAoFwdPjMfObgUHonpIRpVI-EkIUZVzQWKlQUHmBBowKFiguoks06OWg16_Rjfe77pU04gP09bk94heLJ4caXOPx0hZ7wGNb1gUc8MLZdQGlxyufVxs8r6HC06qye93ktnrCk32eQmUAZ86WuNkCXo2WI7zYaldqA22TG110RNr6xh1v0VWmCw93v3eIVq-Tj_F7MJu_TcfPs8BERDWBMQCSKcaN0CI1mRCSAXAgkivB12tOQqPiiEWh0qkWGUmNodxwkYVCxBkLh-jhlFs7-92Cb5KdbV3VVSYspCKUMpK8c5GTyzjrvYMsqV1eandMKEn6SZO_k3YIPiFgbJX7MyBiJiIay747OFm83sC599_IH85Lf-s</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2316377475</pqid></control><display><type>article</type><title>Why Do Experts Solve Complex Problems Using Open Innovation? Evidence from the U.S. Pharmaceutical Industry</title><source>PAIS Index</source><source>SAGE Complete A-Z List</source><creator>Lee, Yeolan ; Fong, Eric ; Barney, Jay Bryan ; Hawk, Ashton</creator><creatorcontrib>Lee, Yeolan ; Fong, Eric ; Barney, Jay Bryan ; Hawk, Ashton</creatorcontrib><description>This article investigates how project expertise and complexity jointly impact the decision to adopt open or closed innovation. It identifies four different types of open innovation models—crowdsourcing, coopetition, science-based, and network—and explores the varying conditions of project expertise and complexity under which firms tend to adopt a particular type. Using large data analysis from pharmaceutical drug development projects, the authors find that complexity moderates the relationship between project expertise and the choice of open or closed innovation and that levels of complexity and project expertise vary between different open innovation models.</description><identifier>ISSN: 0008-1256</identifier><identifier>EISSN: 2162-8564</identifier><identifier>DOI: 10.1177/0008125619883617</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Complexity ; Crowdsourcing ; Data analysis ; Development programs ; Drug development ; Experts ; Innovations ; Pharmaceutical industry</subject><ispartof>California management review, 2019-11, Vol.62 (1), p.144-166</ispartof><rights>The Regents of the University of California 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-ccee72825c6a6dcf6672ee5e075865bb503c8942438ada6f0dcc15c56f3669f23</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/0008125619883617$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/0008125619883617$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,778,782,21808,27855,27913,27914,43610,43611</link.rule.ids></links><search><creatorcontrib>Lee, Yeolan</creatorcontrib><creatorcontrib>Fong, Eric</creatorcontrib><creatorcontrib>Barney, Jay Bryan</creatorcontrib><creatorcontrib>Hawk, Ashton</creatorcontrib><title>Why Do Experts Solve Complex Problems Using Open Innovation? Evidence from the U.S. Pharmaceutical Industry</title><title>California management review</title><description>This article investigates how project expertise and complexity jointly impact the decision to adopt open or closed innovation. It identifies four different types of open innovation models—crowdsourcing, coopetition, science-based, and network—and explores the varying conditions of project expertise and complexity under which firms tend to adopt a particular type. Using large data analysis from pharmaceutical drug development projects, the authors find that complexity moderates the relationship between project expertise and the choice of open or closed innovation and that levels of complexity and project expertise vary between different open innovation models.</description><subject>Complexity</subject><subject>Crowdsourcing</subject><subject>Data analysis</subject><subject>Development programs</subject><subject>Drug development</subject><subject>Experts</subject><subject>Innovations</subject><subject>Pharmaceutical industry</subject><issn>0008-1256</issn><issn>2162-8564</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>7TQ</sourceid><recordid>eNp1kM1Lw0AUxBdRsFbvHhc8p-5ush85idSqhUILtXgM281Lm5pk425S2v_ehAoFwdPjMfObgUHonpIRpVI-EkIUZVzQWKlQUHmBBowKFiguoks06OWg16_Rjfe77pU04gP09bk94heLJ4caXOPx0hZ7wGNb1gUc8MLZdQGlxyufVxs8r6HC06qye93ktnrCk32eQmUAZ86WuNkCXo2WI7zYaldqA22TG110RNr6xh1v0VWmCw93v3eIVq-Tj_F7MJu_TcfPs8BERDWBMQCSKcaN0CI1mRCSAXAgkivB12tOQqPiiEWh0qkWGUmNodxwkYVCxBkLh-jhlFs7-92Cb5KdbV3VVSYspCKUMpK8c5GTyzjrvYMsqV1eandMKEn6SZO_k3YIPiFgbJX7MyBiJiIay747OFm83sC599_IH85Lf-s</recordid><startdate>20191101</startdate><enddate>20191101</enddate><creator>Lee, Yeolan</creator><creator>Fong, Eric</creator><creator>Barney, Jay Bryan</creator><creator>Hawk, Ashton</creator><general>SAGE Publications</general><scope>OQ6</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TQ</scope><scope>8BJ</scope><scope>DHY</scope><scope>DON</scope><scope>FQK</scope><scope>JBE</scope><scope>K9.</scope></search><sort><creationdate>20191101</creationdate><title>Why Do Experts Solve Complex Problems Using Open Innovation? Evidence from the U.S. Pharmaceutical Industry</title><author>Lee, Yeolan ; Fong, Eric ; Barney, Jay Bryan ; Hawk, Ashton</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-ccee72825c6a6dcf6672ee5e075865bb503c8942438ada6f0dcc15c56f3669f23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Complexity</topic><topic>Crowdsourcing</topic><topic>Data analysis</topic><topic>Development programs</topic><topic>Drug development</topic><topic>Experts</topic><topic>Innovations</topic><topic>Pharmaceutical industry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Yeolan</creatorcontrib><creatorcontrib>Fong, Eric</creatorcontrib><creatorcontrib>Barney, Jay Bryan</creatorcontrib><creatorcontrib>Hawk, Ashton</creatorcontrib><collection>ECONIS</collection><collection>CrossRef</collection><collection>PAIS Index</collection><collection>International Bibliography of the Social Sciences (IBSS)</collection><collection>PAIS International</collection><collection>PAIS International (Ovid)</collection><collection>International Bibliography of the Social Sciences</collection><collection>International Bibliography of the Social Sciences</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>California management review</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Yeolan</au><au>Fong, Eric</au><au>Barney, Jay Bryan</au><au>Hawk, Ashton</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Why Do Experts Solve Complex Problems Using Open Innovation? Evidence from the U.S. Pharmaceutical Industry</atitle><jtitle>California management review</jtitle><date>2019-11-01</date><risdate>2019</risdate><volume>62</volume><issue>1</issue><spage>144</spage><epage>166</epage><pages>144-166</pages><issn>0008-1256</issn><eissn>2162-8564</eissn><abstract>This article investigates how project expertise and complexity jointly impact the decision to adopt open or closed innovation. It identifies four different types of open innovation models—crowdsourcing, coopetition, science-based, and network—and explores the varying conditions of project expertise and complexity under which firms tend to adopt a particular type. Using large data analysis from pharmaceutical drug development projects, the authors find that complexity moderates the relationship between project expertise and the choice of open or closed innovation and that levels of complexity and project expertise vary between different open innovation models.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><doi>10.1177/0008125619883617</doi><tpages>23</tpages><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 0008-1256
ispartof	California management review, 2019-11, Vol.62 (1), p.144-166
issn	0008-1256 2162-8564
language	eng
recordid	cdi_proquest_journals_2316377475
source	PAIS Index; SAGE Complete A-Z List
subjects	Complexity Crowdsourcing Data analysis Development programs Drug development Experts Innovations Pharmaceutical industry
title	Why Do Experts Solve Complex Problems Using Open Innovation? Evidence from the U.S. Pharmaceutical Industry
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T09%3A18%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Why%20Do%20Experts%20Solve%20Complex%20Problems%20Using%20Open%20Innovation?%20Evidence%20from%20the%20U.S.%20Pharmaceutical%20Industry&rft.jtitle=California%20management%20review&rft.au=Lee,%20Yeolan&rft.date=2019-11-01&rft.volume=62&rft.issue=1&rft.spage=144&rft.epage=166&rft.pages=144-166&rft.issn=0008-1256&rft.eissn=2162-8564&rft_id=info:doi/10.1177/0008125619883617&rft_dat=%3Cproquest_cross%3E2316377475%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2316377475&rft_id=info:pmid/&rft_sage_id=10.1177_0008125619883617&rfr_iscdi=true